Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 363.5 DKK -0.58% Market Closed
Market Cap: 90.3B DKK

EV/EBITDA
Enterprise Value to EBITDA

8.9
Current
22.1
Median
4.1
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
8.9
=
Enterprise Value
66.5B DKK
/
EBITDA
7.5B DKK
EBITDA Growth EV/EBITDA to Growth
DK
Genmab A/S
CSE:GMAB
Average EV/EBITDA: 15.4
8.9
20%
0.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 934.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.1
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.7
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.7
14%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -290.8 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
7.4
2-Years Forward
EV/EBITDA
6.3
3-Years Forward
EV/EBITDA
5.1